Shandong Jincheng Pharmaceutical and Chemical Co Ltd Total Liabilities
Shandong Jincheng Pharmaceutical and Chemical Co Ltd total liabilities. Based on the latest financial reports, Shandong Jincheng Pharmaceutical and Chemical Co Ltd (300233) has total liabilities worth CN¥1.43 Billion CNY (≈ $208.76 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Shandong Jincheng Pharmaceutical and Che to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shandong Jincheng Pharmaceutical and Chemical Co Ltd (2008–2025)
Total liabilities of Shandong Jincheng Pharmaceutical and Chemical Co Ltd from 2008 to 2025. This chart illustrates how Shandong Jincheng Pharmaceutical and Chemical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Shandong Jincheng Pharmaceutical and Che long-term investment intensity to see how much of total assets are deployed in long-term investments.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Jincheng Pharmaceutical and Chemical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Chunhui Intelligent Control Co. Ltd.
SHE:300943
|
China | CN¥248.56 Million |
|
Beijing Asiacom Information Technology Co.Ltd
SHE:301085
|
China | CN¥718.92 Million |
|
Zee Entertainment Enterprises Limited
NSE:ZEEL
|
India | Rs24.87 Billion |
|
Jenkem Technology Co Ltd
SHG:688356
|
China | CN¥81.71 Million |
|
Suntar Environmental Technology Co
SHG:688101
|
China | CN¥1.60 Billion |
|
Hunan Heshun Petroleum Co Ltd
SHG:603353
|
China | CN¥1.25 Billion |
|
Carlton Investments Ltd
AU:CIN
|
Australia | AU$199.89 Million |
|
Electronics Mart India Limited
NSE:EMIL
|
India | Rs21.71 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Shandong Jincheng Pharmaceutical and Chemical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Shandong Jincheng Pharmaceutical and Che asset portfolio.
Liquidity & Leverage Metrics
Shandong Jincheng Pharmaceutical and Chemical Co Ltd Total Liabilities Ratios Explained
Shandong Jincheng Pharmaceutical and Chemical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Jincheng Pharmaceutical and Chemical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Jincheng Pharmaceutical and Chemical Co Ltd (2008–2025)
The table below shows the annual total liabilities of Shandong Jincheng Pharmaceutical and Chemical Co Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.47 Billion ≈ $214.66 Million |
-17.26% |
| 2024-12-31 | CN¥1.77 Billion ≈ $259.42 Million |
-16.96% |
| 2023-12-31 | CN¥2.14 Billion ≈ $312.42 Million |
-1.47% |
| 2022-12-31 | CN¥2.17 Billion ≈ $317.07 Million |
+18.03% |
| 2021-12-31 | CN¥1.84 Billion ≈ $268.63 Million |
+19.76% |
| 2020-12-31 | CN¥1.53 Billion ≈ $224.30 Million |
+1.68% |
| 2019-12-31 | CN¥1.51 Billion ≈ $220.60 Million |
+25.78% |
| 2018-12-31 | CN¥1.20 Billion ≈ $175.39 Million |
+24.04% |
| 2017-12-31 | CN¥966.24 Million ≈ $141.39 Million |
+28.37% |
| 2016-12-31 | CN¥752.68 Million ≈ $110.14 Million |
+9.73% |
| 2015-12-31 | CN¥685.95 Million ≈ $100.38 Million |
+2.59% |
| 2014-12-31 | CN¥668.61 Million ≈ $97.84 Million |
+20.66% |
| 2013-12-31 | CN¥554.11 Million ≈ $81.08 Million |
+12.11% |
| 2012-12-31 | CN¥494.26 Million ≈ $72.33 Million |
+12.50% |
| 2011-12-31 | CN¥439.36 Million ≈ $64.29 Million |
-24.59% |
| 2010-12-31 | CN¥582.62 Million ≈ $85.26 Million |
+41.74% |
| 2009-12-31 | CN¥411.04 Million ≈ $60.15 Million |
+0.33% |
| 2008-12-31 | CN¥409.67 Million ≈ $59.95 Million |
-- |
About Shandong Jincheng Pharmaceutical and Chemical Co Ltd
Shandong Jincheng Pharmaceutical Group Co., Ltd researches and develops, produces, markets, and sells Cephalosporin pharmaceutical intermediates in China and internationally. It offers medical intermediate, animal nutrition, health care, CMO, CDMO, pharmaceuticals, API, finished dosage, and fine chemicals. The company was founded in 2004 and is based in Zibo, China.